CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets
Cash	$ 3,551,832	$ 534,046
Prepaid drug product for testing	51,364	195,000
Other current assets	64,117	42,575
Total current assets	3,667,313	771,621
Other assets
Technology licenses - related party	2,500,374	2,500,374
Less Accumulated Amortization	(1,088,856)	(928,231)
Intangible Assets, Net (Excluding Goodwill), Total	1,411,518	1,572,143
TOTAL ASSETS	5,078,831	2,343,764
Current liabilities
Accounts payable	76,109	57,000
Accounts payable - related party	0	8,582
Accrued expense	66,739	137,662
Accrued expense - related party	52,050	26,000
Accrued license payments - related party	100,000	100,000
Total current liabilities	294,898	329,244
Long term debt	0	0
TOTAL LIABILITIES	294,898	329,244
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, $.001 par value, 200,000,000 shares authorized 84,237,872 and 62,219,050 shares issued and outstanding as of 12/31/13 and 12/31/12, respectively	84,238	62,218
Additional paid in capital	20,096,991	13,321,075
Additional paid in capital for shares to be issued	0	762,510	[1]
Accumulated deficit during development stage	(15,397,296)	(12,131,283)
Total shareholders' equity	4,783,933	2,014,520
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 5,078,831	$ 2,343,764

[1] Represents 2,541,700 shares of common stock